TY - JOUR
T1 - Web-Based Cognitive-Behavioral Therapy to Reduce Severe Cancer-Related Fatigue Among Survivors of Hodgkin Lymphoma
T2 - A Feasibility Study
AU - Esser, Peter
AU - Müller, Horst
AU - Borchmann, Peter
AU - Kreissl, Stefanie
AU - Knoop, Hans
AU - Platzbecker, Uwe
AU - Vucinic, Vladan
AU - Mehnert-Theuerkauf, Anja
N1 - Funding Information: Open Access funding enabled and organized by Projekt DEAL. This work was supported by the German José Carreras Leukemia Foundation e.V. (Deutsche José Carreras Leukämie-Stiftung e.V.; Grant Number: DJCLS 25 R/2017). The funding institution was not involved at any stage of the research process. Publisher Copyright: © 2023, The Author(s).
PY - 2023/12
Y1 - 2023/12
N2 - We investigated the feasibility of a web-based cognitive-behavioral therapy to reduce cancer-related fatigue (CRF) among survivors of Hodgkin lymphoma. In this before-and-after trial, patients were primarily recruited via the German Hodgkin Study Group (GHSG). We assessed feasibility (response and drop-out rate) and preliminary efficacy including CRF, quality of life (QoL), and depressive symptomatology. T tests compared baseline levels with t1 (post treatment) and t2 (3 months of follow-up). Among 79 patients contacted via the GHSG, 33 provided interest (42%). Among the seventeen participants, four were treated face-to-face (pilot patients), 13 underwent the web-based version. Ten patients completed the treatment (41%). Among all participants, CRF, depressive symptomatology, and QoL improved at t1 (p ≤.03). The effect in one of the CRF measures remained at t2 (p =.03). Except for QoL, post-treatment effects were replicated among the completers of the web-based version (p ≤.04). The potential for this program has been demonstrated, but needs to be re-assessed after identified issues on feasibility have been resolved. Trial registration: The study was registered at ClinicalTrials.gov (Number: NCT03968250).
AB - We investigated the feasibility of a web-based cognitive-behavioral therapy to reduce cancer-related fatigue (CRF) among survivors of Hodgkin lymphoma. In this before-and-after trial, patients were primarily recruited via the German Hodgkin Study Group (GHSG). We assessed feasibility (response and drop-out rate) and preliminary efficacy including CRF, quality of life (QoL), and depressive symptomatology. T tests compared baseline levels with t1 (post treatment) and t2 (3 months of follow-up). Among 79 patients contacted via the GHSG, 33 provided interest (42%). Among the seventeen participants, four were treated face-to-face (pilot patients), 13 underwent the web-based version. Ten patients completed the treatment (41%). Among all participants, CRF, depressive symptomatology, and QoL improved at t1 (p ≤.03). The effect in one of the CRF measures remained at t2 (p =.03). Except for QoL, post-treatment effects were replicated among the completers of the web-based version (p ≤.04). The potential for this program has been demonstrated, but needs to be re-assessed after identified issues on feasibility have been resolved. Trial registration: The study was registered at ClinicalTrials.gov (Number: NCT03968250).
KW - Cancer-related fatigue
KW - Cognitive-behavioral therapy
KW - Hodgkin lymphoma
KW - Online interventions
KW - Survivorship
UR - http://www.scopus.com/inward/record.url?scp=85148453685&partnerID=8YFLogxK
U2 - https://doi.org/10.1007/s10880-023-09944-6
DO - https://doi.org/10.1007/s10880-023-09944-6
M3 - Article
C2 - 36808045
SN - 1068-9583
VL - 30
SP - 856
EP - 865
JO - Journal of clinical psychology in medical settings
JF - Journal of clinical psychology in medical settings
IS - 4
ER -